>
产品中心 >
Primer_Probe >
abfrontier/Cellartis DEF-CS 500无氙三维球体培养基，不含抗生素/Cellartis DEF-CS 500无氙三维球体培养基，不含抗生素，1试剂盒/Y30047
주문정보
- - 재고수량은 변동될 수 있습니다.
- - 재고 확인 시 "갱신" 버튼을 누르시면 실시간 재고를 확인하실 수 있습니다.
- - 가격이 ‘별도문의‘ 시, 상단 ‘견적신청’ 버튼을 눌러 문의해주시면 빠른 답변을 받으실 수 있습니다.
| 선택 | Cat.No. | 제품명 | 가격(VAT별도) | 수량 |
|---|
제품특징
□ 특징
● 배양 용기면적에 의존하지 않는 3D spheroid culture에서 humaniPS/ES세포 배양 scale up에 유용
● 최적화된프로토콜과 배지 첨가제에 의한 뛰어난 확대 배양 효율 (800배 /11일)
● 3D분화유도 전 배양 프로토콜에도 최적
● 안정된 핵형과분화유도능 유지
● Xeno-free: 동물이나 인간 유래 성분 불포함
□ 제품설명
본 제품은 인간 유래 다능성 줄기 세포(human ES / iPS 세포)의 3D spheroid 배양용 배지로 동물이나 인간 유래 성분을포함하지 않는 chemically defined media이다. 배양용기면적에 의존하지 않고, 배양 스케일 업에 유용하다. 본 제품에서배양한 인간 유래 다능성 줄기 세포는 분화 유도 능력 및 핵형을 유지하고 있다.※ Basal Medium에는 GMPgrade 제품(Code Y30071)도있다.본 제품 이용 시 Cellartis® DEF-CS™ 500Xeno-Free 3D Spheroid Additives (Code Y30048)와 조합해서 사용하십시오.
□ 내용
CellartisDEF-CS 500 Xeno-Free 3D Spheroid Culture Medium w/o antibiotics (Code Y30047) | ||
CellartisDEF-CS 500 Xeno-Free Basal Medium w/o Antibiotics | 500 ml | |
CellartisDEF-CS 500 Xeno-Free 3D Spheroid additives | 1 Set; 배지 첨가제 (CodeY30048) | |
- DEF-CS Xeno-Free 3D SpheroidAdditive 1 (1,000×) | 500 ㎕ | |
- DEF-CS Xeno-Free 3D SpheroidAdditive 2 (4,000×) | 200 ㎕ | |
- DEF-CS Xeno-Free 3D SpheroidAdditive 3 (500×) | 400 ㎕ | |
□ 보존
Cellartis DEF-CS 500 Xeno-Free Basal Medium w/o antibiotics : 4℃Cellartis DEF-CS 500 Xeno-Free 3D Spheroid additives：-15℃ 이하
□ Application data
그림 1. High-quality hiPS cell aggregatesgrown with Cellartis DEF-CS 500 Xeno-Free 3D Spheroid Culture Medium in stirredtank bioreactors (in perfusion mode). hiPS cell aggregates grown under 4% O2perfusion conditions were sequentially passaged three times by mechanicaldisruption (protocol adapted from Otsuji et al. 2014); cells were counted atpassage on days 4 and 7, and at the final time point on day 11, to determinethe expansion factor relative to the initial seeding number.
그림 2. High-quality hiPS cell aggregatesgrown with Cellartis DEF-CS 500 Xeno-Free 3D Spheroid Culture Medium in stirredtank bioreactors (in perfusion mode). hiPS cell aggregates were differentiatedinto definitive endoderm cells using a four-day protocol, then furtherdifferentiated into either lung progenitors (left), hepatospheres (middle), orbeta cells (right) via respective 11-15 daydifferentiation protocols. qPCRdata (not shown) indicated increases in FOXA2 and NKX2.1 expression in lungprogenitors; CYP3A4, AFP, and CYP1A in hepatospheres; and PDX1 and NKX6.1 inbeta cells.
그림 3. High-quality hiPS cell aggregatesgrown with Cellartis DEF-CS 500 Xeno-Free 3D Spheroid Culture Medium in stirredtank bioreactors (in perfusion mode). Representative images of aggregates atdays 1, 2, and 5 after seeding with 2.5 x 105 cells/ml. Viable cells werelabeled with fluorescein diacetate (green) and dead cells with propidium iodide(red).
그림 4. High-quality hiPS cell aggregateswere grown with Cellartis DEF-CS 500 Xeno-Free 3D Spheroid Culture Medium instirred tank bioreactors (in perfusion mode). After expansion of hiPS cells asaggregates, cells were harvested on day 4 and expression of OCT4, SSEA-4,TRA-1-60 (pluripotency markers) and SSEA-1 and SOX17 (differentiation markers)was analyzed by immunostaining.
